Bromocriptine

Drug Profile

Bromocriptine

Alternative Names: Bromocriptine mesylate; Bromocriptine-QR; CB 154; Cycloset; Ergoset; PLD 165

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator VeroScience LLC
  • Developer Salix Pharmaceuticals; VeroScience
  • Class Antihyperglycaemics; Antiparkinsonians; Ergolines; Ergotamines; Infertility therapies
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Atherosclerosis; Breast cancer; Obesity

Most Recent Events

  • 01 Jun 2016 VeroScience completes a phase-I clinical trial in Type-2 diabetes mellitus (in children and adolescents) in USA (PO)
  • 17 Apr 2016 Biomarkers information updated
  • 15 Jun 2015 Adverse events data from a phase III trial in Type 2 diabetes mellitus released by VeroScience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top